IMRX — Immuneering Cashflow Statement
0.000.00%
Last trade - 00:00- $352.36m
- $179.53m
Annual cashflow statement for Immuneering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -33.5 | -50.5 | -53.5 | -61 | -56 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.05 | 4.42 | 5.13 | 6.58 | 6.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.9 | 1.72 | -0.975 | -0.925 | 3.82 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.9 | -44.1 | -49 | -55 | -45.3 |
| Capital Expenditures | -0.061 | -0.742 | -0.343 | -0.085 | -0.142 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -75.6 | 42.6 | 7.64 | 26.5 | -88.6 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -75.6 | 41.8 | 7.3 | 26.4 | -88.7 |
| Financing Cash Flow Items | -2.12 | -0.281 | -0.204 | -0.041 | -3.73 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 144 | 0.019 | 28.4 | 5.3 | 227 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 37.8 | -2.25 | -13.2 | -23.3 | 92.5 |